Loading…
Grifols, S.A. is projected to rise to $8.03 by 2027, a +10% move from its current price of $7.27. GRFS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $7.18 | $7.27 | $7.37 | +0.04% |
| Jul 15 | $7.14 | $7.28 | $7.41 | +0.09% |
| Jul 16 | $7.12 | $7.28 | $7.44 | +0.13% |
| Jul 17 | $7.10 | $7.28 | $7.47 | +0.17% |
| Jul 18 | $7.08 | $7.29 | $7.50 | +0.22% |
| Jul 19 | $7.06 | $7.29 | $7.52 | +0.26% |
| Jul 20 | $7.05 | $7.29 | $7.55 | +0.31% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.05 | $7.29 | $7.55 | +0.31% |
| Week 2 | $6.97 | $7.31 | $7.68 | +0.61% |
| Week 3 | $6.91 | $7.34 | $7.79 | +0.92% |
| Week 4 | $6.87 | $7.36 | $7.88 | +1.23% |
| Week 5 | $6.84 | $7.38 | $7.97 | +1.54% |
| Week 6 | $6.81 | $7.40 | $8.05 | +1.85% |
| Week 7 | $6.78 | $7.43 | $8.13 | +2.16% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Grifols, S.A. engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.
It markets diagnostic testing equipment, reagents, and other equipment, and provides transfusion medicine, clinical diagnostics, and testing services. It offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use.
In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services.
The company was founded in 1909 and is headquartered in Barcelona, Spain.
Grifols, S.A. (GRFS) is a healthcare company with a diversified business in plasma-derived medicines and related services.
Its current price is $7.29 and its market capitalization is $4.96B, with a market rank of 1387.
The forecast implies a path higher over the coming years, with 2026 avg price $7.29, rising to 2030 avg $9.63 and 2050 avg $36.55, and a 2050 max of $59.77. The 2026 min and max are $7.08 and $9.40, respectively. The forecast sentiment is NEUTRAL in 2026 and turns BULLISH from 2029 onward, with rising upside into the 2040s and 2050.
Overall, the outlook suggests a constructive longer-term trajectory, albeit with near term volatility and an equal emphasis on risk and uncertainty inherent in any forecast.
A major floor 10.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.6% away) — a key level to hold.
The nearest ceiling, 9.8% above — a clean break opens room to run.
A major ceiling 20.5% above — clearing it would confirm fresh momentum.
Key GRFS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GRFS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $7.25 | Buy | $7.26 | Buy |
| MA 10 | $7.23 | Buy | $7.26 | Buy |
| MA 20 | $7.33 | Sell | $7.33 | Sell |
| MA 50 | $7.65 | Sell | $7.60 | Sell |
| MA 100 | $8.01 | Sell | $7.95 | Sell |
| MA 200 | $8.60 | Sell | $8.31 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.89 | Neutral |
| Stoch RSI (14) | 86.09 | Sell |
| CCI (20) | -28.21 | Neutral |
| Williams %R (14) | -38.71 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 1.25 | Buy |
| Bollinger %B (20,2) | 0.41 | Neutral |
| Stochastic %K (14) | 61.29 | Neutral |
| TRIX (15) | -0.28 | Sell |
| Awesome (5,34) | -0.24 | Sell |
| Ultimate (7,14,28) | 66.58 | Neutral |
| Momentum (10) | -0.10 | Sell |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 7.31 | Sell |
| ADX (14) | 17.81 | Neutral |
| ATR (14) | 0.08 | Info |
The 30-day technical picture is NEUTRAL, with RSI14 at 40. The 50-day simple moving average sits at $7.66 and the 200-day simple moving average at $8.61.
Support is at $7.08 and resistance at $8.05. The 30-day price range runs from a low of $6.68 to a high of $7.96, highlighting a tight near-term trading band.
Annualized volatility stands around 30%, reflecting meaningful but manageable near-term price fluctuations.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.08 | $7.27 | $9.36 | 0% | Neutral | |
| $6.57 | $8.03 | $10.25 | +10% | Neutral | |
| $6.95 | $8.64 | $11.33 | +19% | Neutral | |
| $7.10 | $8.96 | $12.00 | +23% | Bullish | |
| $7.43 | $9.51 | $12.97 | +31% | Bullish | |
| $8.20 | $10.62 | $14.71 | +46% | Bullish | |
| $9.59 | $12.57 | $17.65 | +73% | Bullish | |
| $10.35 | $13.70 | $19.49 | +88% | Bullish | |
| $10.16 | $13.59 | $19.57 | +87% | Bullish | |
| $10.73 | $14.48 | $21.08 | +99% | Bullish | |
| $15.17 | $21.36 | $32.57 | +194% | Bullish | |
| $23.51 | $35.50 | $58.05 | +388% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $7.08 | $7.27 | $8.65 | +0.00% |
| August 2026 | $6.44 | $7.53 | $9.01 | +3.63% |
| September 2026 | $6.43 | $7.56 | $9.12 | +0.41% |
| October 2026 | $6.29 | $7.43 | $9.01 | -1.77% |
| November 2026 | $6.32 | $7.50 | $9.14 | +0.86% |
| December 2026 | $6.42 | $7.64 | $9.36 | +1.89% |
Click any year to see its month-by-month GRFS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect GRFS to range from $7.08 to $9.36 through 2026. The $7.27 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The GRFS price prediction for 2027 points to an average of $8.03 (low $6.57, high $10.25) — a potential gain of +10% on today's $7.27. Price action looks broadly range-bound.
In 2028, GRFS is projected to trade between $6.95 and $11.33, averaging $8.64 — a potential gain of +19% from today's $7.27. That is up +8% on the projected 2027 average. A consolidation phase looks the most probable path here.
Grifols, S.A.'s 2029 outlook centres on $8.96, within a $7.10 to $12.00 range. That is up +4% on the projected 2028 average. That marks a +23% change versus current levels. Momentum favours further upside here.
By 2030, GRFS could reach as high as $12.97, with a base case around $9.51 and support toward $7.43 — roughly +31% from $7.27. Buyers look set to stay in control over this stretch.
Expect GRFS to range from $8.20 to $14.71 through 2031. The $10.62 average target implies a +46% move from current prices. That is up +12% on the projected 2030 average. Momentum favours further upside here.
The GRFS price prediction for 2032 points to an average of $12.57 (low $9.59, high $17.65) — a potential gain of +73% on today's $7.27. Buyers look set to stay in control over this stretch.
In 2033, GRFS is projected to trade between $10.35 and $19.49, averaging $13.70 — a potential gain of +88% from today's $7.27. That is up +9% on the projected 2032 average. Momentum favours further upside here.
Grifols, S.A.'s 2034 outlook centres on $13.59, within a $10.16 to $19.57 range. That is -1% versus the projected 2033 average. That marks a +87% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, GRFS could reach as high as $21.08, with a base case around $14.48 and support toward $10.73 — roughly +99% from $7.27. Momentum favours further upside here.
Expect GRFS to range from $15.17 to $32.57 through 2040. The $21.36 average target implies a +194% move from current prices. That is up +47% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The GRFS price prediction for 2050 points to an average of $35.50 (low $23.51, high $58.05) — a potential gain of +388% on today's $7.27. Momentum favours further upside here.
Investing $1,000 in GRFS today (≈ 137.551582 GRFS) could be worth
$4,883.74
+$3,883.74 (+388%) by 2050 · US Dollar
Based on the average projected GRFS price of $35.5 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GRFSwould be worth at today's price.
$1,000 invested in GRFS on Jul 10, 2025 (≈ 102.564103 GRFS) would be worth
$745.64
-$254.36 (-25.4%) today · 0.75× · US Dollar
Based on a GRFS entry price of $9.75 vs. today's $7.27.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $7.16 | $1,015.36 | +1.5% |
| 1 month ago | $7.32 | $993.17 | -0.7% |
| 3 months ago | $8.21 | $885.51 | -11.4% |
| 6 months ago | $9.14 | $795.4 | -20.5% |
| 1 year ago | $9.75 | $745.64 | -25.4% |
| All time (5.0y) ago | $15.85 | $458.68 | -54.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GRFS forecast.
Our base-case forecast reaches $15.00 around 2040.
Implied market cap at $15.00: $3.87B
The multi-year forecast shows a steady but gradual rise from the 2026 base. The 2026 avg price is $7.29, with the 2027 avg $8.07 and the 2028 avg $8.74, yielding ROIs of 10.7% and 19.9% respectively, under a NEUTRAL outlook for those years.
By 2029 the average price reaches $9.06 with a 24.3% ROI and the trend remains BULLISH through 2030 (avg $9.63, ROI 32.2%). From 2031 onward, the forecast shows stronger gains: 2031 avg $10.84 (ROI 48.7%), 2032 avg $12.80 (ROI 75.6%), 2033 avg $13.94 (ROI 91.2%), 2034 avg $13.88 (ROI 90.4%), and 2035 avg $14.79 (ROI 102.8%).
The horizon extends to 2040 with avg $21.95 (ROI 201%) and to 2050 with avg $36.55 (ROI 401.4%), with a 2050 max of $59.77. Across this period the sentiment remains BULLISH from 2029 onward, reflecting the projected upside potential despite the inherent uncertainties of forward-looking estimates.
Tap a question to reveal the answer.
The 2030 forecast shows min $7.53, avg $9.63, max $13.13 with a 32.2% ROI and bullish sentiment.
Forecasts show rising average prices from 2026 to 2050, with 2026 avg $7.29 and 2050 avg $36.55; ROI grows from 0% in 2026 to 401.4% in 2050, and sentiment is bullish from 2029 onward.
Yes, the 2031 max is $15.01, with 2032 max $17.98, indicating the potential to reach around that level in the period.
Current price is $7.29; 30-day range is $6.68 to $7.96.
2050 min $24.20, avg $36.55, max $59.77 with ROI 401.4% and sentiment BULLISH.
Grifols, S.A. Community Discussion
0Share your Grifols, S.A. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.